Magnesium Gluconate Anhydrous
CAS 3632-91-5
Magnesium Gluconate Anhydrous (CAS 3632-91-5) is a pharmaceutical compound with 0 bioactivity targets and 23 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Body tinea | 26 | 131.141 | 10005913 |
| Infection susceptibility increased | 28 | 122.442 | 10021866 |
| Inhibitory drug interaction | 26 | 109.748 | 10068071 |
| Glucose tolerance impaired | 27 | 95.473 | 10018429 |
| Bone density decreased | 27 | 80.578 | 10049470 |
| Poor quality sleep | 28 | 71.418 | 10062519 |
| Purpura | 26 | 71.363 | 10037549 |
| Hyperlipidaemia | 28 | 67.183 | 10062060 |
| Oral herpes | 28 | 66.811 | 10067152 |
| Impaired quality of life | 24 | 66.367 | 10076936 |
| Impaired work ability | 24 | 61.141 | 10052302 |
| Discoloured vomit | 13 | 60.915 | 10079120 |
| SARS-CoV-2 sepsis | 9 | 59.152 | 10084639 |
| Skin disorder | 26 | 53.49 | 10040831 |
| Cataract | 32 | 52.156 | 10007739 |
| Cellulitis | 36 | 48.013 | 10007882 |
| Anaemia | 60 | 36.935 | 10002034 |
| Internal haemorrhage | 13 | 36.373 | 10075192 |
| Herpes zoster | 28 | 33.566 | 10019974 |
| Fatigue | 91 | 27.824 | 10016256 |
| Contusion | 31 | 27.806 | 10050584 |
| Hallucination, auditory | 13 | 25.477 | 10019070 |
| Pre-existing condition improved | 10 | 25.382 | 10036495 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Magnesium Gluconate Anhydrous used for in pharmaceutical contexts?
Magnesium Gluconate Anhydrous (CAS 3632-91-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Magnesium Gluconate Anhydrous?
Magnesium Gluconate Anhydrous has 23 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Body tinea, Infection susceptibility increased, Inhibitory drug interaction, Glucose tolerance impaired, Bone density decreased. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Magnesium Gluconate Anhydrous also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Magnesium Gluconate with EU status "permitted".
What clinical phase is Magnesium Gluconate Anhydrous in?
No phase 1-4 clinical development badge is rendered for Magnesium Gluconate Anhydrous because the matched compound identifier rows do not contain a max-phase value.